20 articles
ASTER 70s trial compares treatment intensities for women 70+ with genomically high-risk breast cancer to optimize outcomes while minimizing toxicity.
New study finds 27% of patients with treatment-resistant hypertension have elevated cortisol levels that could explain medication failures.
A randomized trial shows hormone receptor-positive/HER2+ early breast cancer patients had 100% 5-year overall survival with endocrine therapy plus dual HER2 blockade.
A comprehensive review in CA Cancer J Clin maps the molecular biology, treatment strategies, and equity gaps in high-grade serous ovarian cancer.
Metabolite supplement protects heart from chemo toxicity and enhances tumor suppression in breakthrough dual-action study.
HIIT training studied in 52 men with prostate cancer on active surveillance to evaluate exercise benefits during watchful waiting.
Researchers use advanced cell profiling to develop personalized immune treatments for thyroid cancer patients.
Novel nanoparticle combines protein degrader with light therapy to reprogram cancer metabolism and eliminate breast tumors.
A 10-week supervised strength program targets chronic inflammation and self-efficacy in long-term allogeneic HCT survivors.
New research identifies HBO1 as a key driver of cancer cell transformation and resistance to CAR-T cell therapy in ovarian cancer.
New review reveals how HER2 reshapes the tumor immune environment — and why beating it requires more than blocking the oncogene.
Northwestern researchers dramatically boosted cancer vaccine effectiveness by simply repositioning one protein fragment on their nanovaccine.
New combination strategies show promise for overcoming immune resistance in head and neck cancers through targeted biomarker approaches.
Bireociclib plus fulvestrant significantly improved outcomes in advanced hormone-positive breast cancer patients.
Researchers found that stopping HER2 protein degradation significantly improves trastuzumab deruxtecan cancer treatment outcomes.
Comprehensive review reveals surgical and emerging biomarker approaches that significantly reduce cancer risk for women with Lynch syndrome.
Ketogenic diet metabolite enhances CAR T cell metabolism and tumor control in multiple cancer models
New consensus on genetic testing for cancer drugs creates fresh questions about finding the right dose for each patient.
The BEGONIA trial finds durvalumab combined with trastuzumab deruxtecan achieves 62% response rate in hard-to-treat metastatic breast cancer.
A newly identified lipid mediator may explain why immune cells fail to fight MASH-driven liver cancer, opening therapeutic targets.
